| P/E (FY) | — | Sales (TTM) | $119.0M |
| Earnings (TTM) | -$73.0M | ROE | — |
| Net Margin | −73.02% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Beta Bionics is a commercial-stage medical device company that designs, develops, and commercializes solutions for insulin-requiring people with diabetes. It offers the iLet Bionic Pancreas, an insulin delivery device for type 1 diabetes in adults and children aged six and older, and is developing a Patch Pump, a bihormonal iLet delivering insulin and glucagon, and an iLet for insulin-dependent type 2 diabetes, with agreements with Xeris Pharmaceuticals and Abbott Diabetes Care.
| Market Cap | $682.5M | Trading Days | 365 |
| 52W High | 32.71 |
| 52W Low | 8.80 |
| % Off High | −53.62% |
| YTD | −50.21% | 1Y | 3.48% |
| Since incept. (ann.) | −25.70% |
| Ann. Volatility (1Y) | 85.35% | Ann. Volatility (3Y) | 87.32% |
| Sharpe (1Y) | 0.54 | Sharpe (3Y) | 0.09 |
| Max Drawdown (1Y) | −72.30% | Max Drawdown (3Y) | −72.30% |
| Beta (3Y, vs SPY) | 2.86 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SGP | SpyGlass Pharma, Inc. | $732.5M | — |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | $618.0M | 33.4 |
| MDXG | MIMEDX GROUP, INC. | $616.6M | 13.2 |
| ANGO | ANGIODYNAMICS INC | $604.7M | — |
| SSII | SS Innovations International, Inc. | $770.5M | — |
| CERS | CERUS CORP | $575.1M | — |
| SIBN | SI-BONE, Inc. | $817.8M | — |
| BVS | Bioventus Inc. | $904.2M | 39.8 |
| KIDS | ORTHOPEDIATRICS CORP | $513.4M | — |
| OFIX | Orthofix Medical Inc. | $491.9M | — |
| SI | SHOULDER INNOVATIONS, INC. | $491.9M | — |
| NeuroPace Inc |
| $465.0M |
| — |